Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      NO_LONGER_AVAILABLE
      Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
      Description

      Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.

      Conditions
      Cancers With NTRK, ROS1, or ALK Gene Fusions
      Talk to us
      ACTIVE_NOT_RECRUITING
      Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
      Description

      This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

      Conditions
      Breast CancerCholangiocarcinomaColorectal CancerHead and Neck NeoplasmsLymphoma, Large-Cell, AnaplasticMelanomaNeuroendocrine TumorsNon-Small Cell Lung CancerOvarian CancerPancreatic CancerPapillary Thyroid CancerPrimary Brain TumorsRenal Cell CarcinomaSarcomasSalivary Gland CancersAdult Solid Tumor
      Talk to us